(Q37827918)

23 August 2017

title

Yield of imaging and scintigraphy assessing biochemical failure in prostate cancer patients (English)

1 reference

23 August 2017

1 reference

1 reference

Johnstone PA

1

1 reference

23 August 2017

Tarman GJ

2

1 reference

23 August 2017

Riffenburgh R

3

1 reference

23 August 2017

Rohde DC

4

1 reference

23 August 2017

Puckett ML

5

1 reference

23 August 2017

Kane CJ

6

1 reference

23 August 2017

publication date

1 July 1997

1 reference

23 August 2017

1 reference

23 August 2017

volume

3

1 reference

23 August 2017

issue

4

1 reference

23 August 2017

page(s)

108-112

1 reference

Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy.

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2898%2900007-6

7 January 2021

Long-Term (15 Years) Results After Radical Prostatectomy For Clinically Localized (Stage T2c Or Lower) Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2898%2900007-6

7 January 2021

Delayed/salvage radiation therapy in patients with elevated prostate specific antigen levels after radical prostatectomy. A long term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2898%2900007-6

7 January 2021

Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2898%2900007-6

7 January 2021

Cancer statistics, 1997.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2898%2900007-6

7 January 2021

Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2898%2900007-6

7 January 2021

Using prostate-specific antigen to eliminate unnecessary diagnostic tests: significant worldwide economic implications

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2898%2900007-6

7 January 2021

The Incidence and Significance of Detectable Levels of Serum Prostate Specific Antigen After Radical Prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2898%2900007-6

7 January 2021

Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2898%2900007-6

7 January 2021

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2898%2900007-6

7 January 2021

The role of imaging in screening for prostate cancer. A decision analysis perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2898%2900007-6

7 January 2021

CT screening for comorbid disease in patients with prostatic carcinoma: is it cost-effective?

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2898%2900007-6

7 January 2021

Is preoperative computed tomography necessary in the management of patients treated for carcinoma of the prostate by 125iodine interstitial implantation and bilateral pelvic lymphadenectomy?

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2898%2900007-6

7 January 2021

Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG phase III study for A2 and B prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2898%2900007-6

7 January 2021

Comparison of pathologic and clinical evaluation of lymph nodes in prostate cancer: implications of RTOG data for patient management and trial design and stratification

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2898%2900007-6

7 January 2021

10.1016/S1078-1439(98)00007-6

Identifiers

DOI

1 reference

23 August 2017

1 reference